NDA for proton pump inhibitor Prevacid (lansoprazole) filed with FDA on Nov. 21, the Takeda Chemical Industries/Abbott Labs joint venture reports Feb. 10. Indications being sought in the NDA include the short-term treatment of duodenal ulcers; short-term and maintenance treatment of reflux esophagitis; and long-term treatment of pathologic hypersecretory conditions including Zollinger-Ellison syndrome
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth